Denosumab discontinuation risk — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Myocardial infarction within the previous year
Romosozumab has an important cardiovascular warning and should not be used in patients with myocardial infarction or stroke in the preceding year. Overall cardiovascular risk, calcium status and the planned subsequent antiresorptive therapy should be considered before treatment.
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/musculoskeletal-conditions